Mohamad Hussein

Mohamad's academic career started at the University of Maryland Cancer center (1989 - 1991). He relocated to the Cleveland Clinic in the summer of 1991 where he created and directed the Multiple Myeloma Research Program from 1996-2006. In January 2006, he was appointed Director, Malignant Hematology Division and Myeloma Section at the H. Lee Moffitt Cancer Center and the University of South Florida in Tampa from 2006-2008.

​

Currently, Mohamad is Professor of Medicine and Oncology at the University of South Florida (2009-Now). During this period, he has developed multidisciplinary approaches to the understanding and therapy of hematologic malignancies. This included developing Phase 1, 2 and 3 compounds through chairing and leading different NCI disease cooperative groups and committees, as well as partnering with pharma. One distinguishing aspect of the CCF program was the use of cellular and skeletal therapeutic and supportive approaches to manage multiple myeloma in general, as well as end-organ damage resulting from the disease.

​

In August 2008, Dr. Hussein joined Celgene Corporation, where he held different positions in hematology while leading the development of the multiple myeloma franchise strategy and driving the clinical development of the Celgene cell therapy placental program. He retired from Celgene in the summer of 2019 as Corporate Vice President, Global Medical Affairs, Multiple Myeloma and Hematology Scientific Collaborations.

He has 150+ published peer-review manuscripts, book chapters, and editorials. Prof. Hussein is currently serving as an ad hoc reviewer for JCO, Haematologica, BMT Journal and The British Journal of Haematology. He also serves as a reviewer on the LLS and FNIH scientific grant review committees. His interest and contributions have focused on advancing the therapeutic programs in hematologic malignancies at Celgene Corporation. Mohamad's current role focuses on studying disease pathophysiology and developing cellular and immune therapy while creating a fully integrated multiple myeloma therapeutic.